CollPlant Files Patent for 3D Bio-Printing of Organs and Tissues
NESS ZIONA, Israel, June 12, 2017 /PRNewswire/ --
CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has filed a patent application in the United States for bio-ink based on its rhCollagen, for three-dimensional printing of tissues and organs. The patent application is a part of the company's strategy to establish its position as a leader in 3D bio-printing, and as a basis for collaborations with leading companies in the field of organ printing, in which CollPlant will constitute the biological ink supplier, in various formulations.
The patent application refers to formulations of biological ink based on recombinant human collagen, which is an ideal building block for bio-ink. CollPlant's bio-ink enables the printing of three-dimensional scaffolds combined with human cells and / or growth factors as a basis for tissue or organ formation. In addition to the collagen, CollPlant's bio-ink formulations can include other proteins and/or polymers, they are compatible with various 3D bio-printing technologies, and to the printed organ Characteristics.
Yehiel Tal, CollPlant's Chief Executive Officer, noted, "We are promoting commercial collaborations with leading international companies in the field of 3D bio-printing of tissue and organ, with the aim of taking part in providing a solution to the significant need for life saving organs. This market need represents high economic potential for the company. The new patent establishes CollPlant's technology status in 3D biological printing, creates barriers to entry for competitors and increases the trust of potential partners. CollPlant's technology is highly regarded by major international players, and our objective is to enter into our first significant collaboration this year."
CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant's business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.
For more information about CollPlant, visit http://www.collplant.com
Contact at CollPlant:
Chief Financial Officer
Contact at Rx Communications Group, LLC
Paula Schwartz (for US Investors)
Released June 12, 2017